Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

32.67 -1.01 (-2.98%)
Streaming Delayed Price Updated: 2:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 199,159
Open 33.91
Bid (Size) 32.54 (300)
Ask (Size) 32.82 (100)
Prev. Close 33.68
Today's Range 32.65 - 34.34
52wk Range 5.350 - 38.69
Shares Outstanding 44,188,534
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire

Performance

YTD
+5.7%
+5.7%
1 Month
+7.2%
+7.2%
3 Month
+9.3%
+9.3%
6 Month
+171.4%
+171.4%
1 Year
+264.7%
+264.7%

More News

Read More
News headline image
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
Via Chartmill
News headline image
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
6 Analysts Have This To Say About Stoke Therapeutics ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Examining the Future: Stoke Therapeutics's Earnings Outlook ↗
Via Benzinga
News headline image
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
What 4 Analyst Ratings Have To Say About Stoke Therapeutics ↗
Via Benzinga
News headline image
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Stoke Therapeutics, Inc. - Common Stock publicly traded?
Yes, Stoke Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Stoke Therapeutics, Inc. - Common Stock trade on?
Stoke Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Stoke Therapeutics, Inc. - Common Stock?
The ticker symbol for Stoke Therapeutics, Inc. - Common Stock is STOK on the Nasdaq Stock Market
What is the current price of Stoke Therapeutics, Inc. - Common Stock?
The current price of Stoke Therapeutics, Inc. - Common Stock is 32.67
When was Stoke Therapeutics, Inc. - Common Stock last traded?
The last trade of Stoke Therapeutics, Inc. - Common Stock was at 01/09/26 02:00 PM ET
What is the market capitalization of Stoke Therapeutics, Inc. - Common Stock?
The market capitalization of Stoke Therapeutics, Inc. - Common Stock is 1.44B
How many shares of Stoke Therapeutics, Inc. - Common Stock are outstanding?
Stoke Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.